Online citations, reference lists, and bibliographies.

Pancreatic Neuroendocrine Tumors: The Impact Of Surgical Resection On Survival.

Joshua S. Hill, James T. McPhee, Theodore P. McDade, Zheng Zhou, Mary E. Sullivan, Giles Francis Whalen, Jennifer Tseng
Published 2009 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Although surgical resection is generally recommended for patients with localized pancreatic neuroendocrine tumors (PNETs), the impact of resection on overall survival is unknown. The authors investigated the survival advantage of pancreatic resection using a national database. METHODS This is a retrospective survival analysis of patients with PNETs from the Surveillance, Epidemiology, and End Results database (1988-2002). RESULTS A total of 728 patients with PNETs were identified with a median survival of 43 months using Kaplan-Meier survival methods. Resection of tumor was associated with significantly improved survival compared with those patients who were recommended for but did not undergo resection (114 months vs 35 months; P < .0001). This survival benefit was demonstrated for patients with localized, regional, and metastatic disease. A multivariable Cox proportional hazards model was constructed to assess the overall effect of surgical resection on survival, and demonstrated an adjusted odds ratio of 0.48 (95% confidence interval, 0.35-0.66) compared with those who were recommended for surgery but did not proceed to surgery. CONCLUSIONS The authors have demonstrated in a large national study that resection of primary tumor in patients with PNETs is associated with improved survival across all disease stages. Patients with localized, regional, and metastatic PNETs who are reasonable operative candidates should be considered for resection of their primary tumors.



This paper is referenced by
10.1016/j.surg.2013.08.002
Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors.
Stefano Crippa (2014)
10.4103/eus.eus_28_19
EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat?
Alberto Larghi (2019)
10.1007/s11605-010-1351-3
Potential Benefit of Resection for Stage IV Gastric Cancer: A National Survey
Jillian K. Smith (2010)
10.1016/J.ANDO.2019.04.009
Gastroenteropancreatic neuroendocrine tumors: Role of surgery.
Alain Sauvanet (2019)
10.1007/978-3-662-47181-4_13
Guideline for the Management of Pancreatic Neuroendocrine Tumor
Gabriele Spoletini (2017)
10.1016/j.clinre.2020.04.003
Surgical resection of primary tumor is associated with prolonged survival in low-grade pancreatic neuroendocrine tumors.
Yaqing Sun (2020)
10.1016/j.critrevonc.2019.102835
Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification.
Hirotaka Ishida (2019)
10.1002/jso.24116
Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms.
Alexander Kaltenborn (2016)
10.1007/s11605-010-1225-8
Surgical Resection and Multidisciplinary Care for Primary and Metastatic Pancreatic Islet Cell Carcinomas
Shaun P McKenzie (2010)
10.1245/s10434-014-3981-2
Impact of 68Ga-DOTATATE PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum
Harun Ilhan (2014)
10.4103/0366-6999.171427
Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors
Yu Yong Jiang (2015)
10.1016/j.ciresp.2016.12.006
Nonfunctioning, small, incidental pancreatic neuroendocrine tumors: Results of a nonoperative approach cohort.
Catalina Uribe Galeano (2017)
10.1007/s00423-020-01868-1
Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry
Nehara Begum (2020)
10.1097/MD.0000000000002224
High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
Yoon Suk Lee (2015)
10.1097/MPA.0000000000000572
Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
Tahsin Khan (2016)
10.1016/j.soc.2019.11.008
Surgical Management of Pancreatic Neuroendocrine Tumors.
Tanaz Vaghaiwalla (2020)
10.5833/JJGS.2015.0058
Intraductal Growth of a Pancreatic Glucagonoma
Tatsuto Terada (2016)
10.1002/9781118512074.ch57
57. Zollinger–Ellison Syndrome
Robert T. Jensen (2015)
10.1007/s00292-014-1971-6
Klassifikation und malignes Potenzial der zystischen Pankreastumoren
I. Esposito (2014)
10.4155/cli.11.120
Advances in the management and treatment of gastroenteropancreatic neuroendocrine tumors
Eric Feliberti (2011)
10.1186/1471-2407-10-448
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
Song Kim (2009)
10.1097/RLU.0000000000000756
99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
Zhen Qiao (2015)
10.1016/j.jchirv.2020.04.015
[Endocrine surgery during and after the COVID-19 epidemic: guidelines from AFCE].
Grégory Baud (2020)
10.1111/j.1477-2574.2010.00198.x
Long-term survival after surgical management of neuroendocrine hepatic metastases.
Evan S Glazer (2010)
10.1055/A-0604-2924
S2k-Leitlinie Neuroendokrine Tumore
Verdauungs und Stoffwechselkrankheiten Deutsche Gesellschaft Gastroenterologie (2018)
10.1016/j.gie.2014.12.031
Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis.
Paul Damien James (2015)
10.3109/00365521003782363
Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems
Ewa Pomianowska (2010)
10.1055/S-0038-1675758
Surgery for Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
Mark S. Etherington (2019)
10.1111/1744-1633.12364
Surgical strategy for neuroendocrine liver metastases
Andrew K. Y. Fung (2019)
10.1002/jso.24338
Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
Lauren McLendon Postlewait (2016)
10.1155/2015/538948
A Single Centre Analysis of Clinical Characteristics and Treatment of Endocrine Pancreatic Tumours
Mohammad Adil (2015)
10.1007/s13691-019-00368-4
Primary small cell neuroendocrine carcinoma of adrenal gland
Kosuke Ogawa (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar